Literature DB >> 31611333

Acupuncture for Chemotherapy-Induced Peripheral Neuropathy in Breast Cancer Survivors: A Randomized Controlled Pilot Trial.

Weidong Lu1, Anita Giobbie-Hurder2, Rachel A Freedman3, Im Hee Shin4, Nancy U Lin3, Ann H Partridge3, David S Rosenthal3, Jennifer A Ligibel3.   

Abstract

BACKGROUND: Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most debilitating long-term side effects in breast cancer survivors. We conducted a randomized controlled pilot trial to assess the feasibility, safety, and effects of an acupuncture intervention on CIPN in this population. PATIENTS AND METHODS: Women with stage I-III breast cancer with grade 1 or higher CIPN after taxane-containing adjuvant chemotherapy were randomized 1:1 to an immediate acupuncture (IA) arm or to a waitlist control group (CG). Participants in the IA arm received 18 sessions of acupuncture over 8 weeks, then received no additional acupuncture. Patients in the CG arm received usual care over 8 weeks, followed by nine sessions of acupuncture over 8 weeks. Measures including Patient Neurotoxicity Questionnaire (PNQ), Functional Assessment of Cancer Therapy-Neurotoxicity subscale (FACT-NTX), and Brief Pain Inventory-short form (BPI-SF) were collected at baseline and at 4, 8, and 16 weeks after enrollment.
RESULTS: Forty women (median age, 54) were enrolled (20 to IA and 20 to CG), with median time between completion of chemotherapy and enrollment of 14 months (range 1-92). At 8 weeks, participants in the IA arm experienced significant improvements in PNQ sensory score (-1.0 ± 0.9 vs. -0.3 ± 0.6; p = .01), FACT-NTX summary score (8.7 ± 8.9 vs. 1.2 ± 5.4; p = .002), and BPI-SF pain severity score (-1.1 ± 1.7 vs. 0.3 ± 1.5; p = .03), compared with those in the CG arm. No serious side effects were observed.
CONCLUSION: Women with CIPN after adjuvant taxane therapy for breast cancer experienced significant improvements in neuropathic symptoms from an 8-week acupuncture treatment regimen. Additional larger studies are needed to confirm these findings. IMPLICATIONS FOR PRACTICE: Chemotherapy-induced peripheral neuropathy (CIPN) is a toxicity that often persists for months to years after the completion of adjuvant chemotherapy for early breast cancer. In a randomized pilot trial of 40 breast cancer survivors with CIPN, an 8-week acupuncture intervention (vs. usual care) led to a statistically and clinically significant improvement in subjective sensory symptoms including neuropathic pain and paresthesia. Given the lack of effective therapies and established safety profile of acupuncture, clinicians may consider acupuncture as a treatment option for mild to moderate CIPN in practice. © AlphaMed Press 2019.

Keywords:  Acupuncture; Breast cancer survivors; Chemotherapy‐induced peripheral neuropathy; Quality of life; Taxane

Year:  2019        PMID: 31611333     DOI: 10.1634/theoncologist.2019-0489

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  35 in total

1.  Standards for Reporting Interventions in Controlled Trials of Acupuncture: the STRICTA recommendations.

Authors:  Hugh MacPherson; Adrian White; Mike Cummings; Kim A Jobst; Ken Rose; Richard C Niemtzow
Journal:  J Altern Complement Med       Date:  2002-02       Impact factor: 2.579

2.  Long-term Peripheral Neuropathy in Breast Cancer Patients Treated With Adjuvant Chemotherapy: NRG Oncology/NSABP B-30.

Authors:  Hanna Bandos; Joy Melnikow; Donna R Rivera; Sandra M Swain; Keren Sturtz; Louis Fehrenbacher; James L Wade; Adam M Brufsky; Thomas B Julian; Richard G Margolese; Edward C McCarron; Patricia A Ganz
Journal:  J Natl Cancer Inst       Date:  2018-02-01       Impact factor: 13.506

Review 3.  Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis.

Authors:  Marta Seretny; Gillian L Currie; Emily S Sena; Sabrina Ramnarine; Robin Grant; Malcolm R MacLeod; Leslie A Colvin; Marie Fallon
Journal:  Pain       Date:  2014-09-23       Impact factor: 6.961

4.  Falls, Functioning, and Disability Among Women With Persistent Symptoms of Chemotherapy-Induced Peripheral Neuropathy.

Authors:  Kerri M Winters-Stone; Fay Horak; Peter G Jacobs; Phoebe Trubowitz; Nathan F Dieckmann; Sydnee Stoyles; Sara Faithfull
Journal:  J Clin Oncol       Date:  2017-06-06       Impact factor: 44.544

Review 5.  Chemotherapy-induced peripheral neuropathy clinical trials: Review and recommendations.

Authors:  Jennifer S Gewandter; Roy Freeman; Rachel A Kitt; Guido Cavaletti; Lynn R Gauthier; Michael P McDermott; Nimish A Mohile; Supriya G Mohlie; A Gordon Smith; Mohamedtaki A Tejani; Dennis C Turk; Robert H Dworkin
Journal:  Neurology       Date:  2017-07-26       Impact factor: 9.910

6.  Measuring the side effects of taxane therapy in oncology: the functional assesment of cancer therapy-taxane (FACT-taxane).

Authors:  David Cella; Amy Peterman; Stacie Hudgens; Kimberly Webster; Mark A Socinski
Journal:  Cancer       Date:  2003-08-15       Impact factor: 6.860

Review 7.  Pain assessment: global use of the Brief Pain Inventory.

Authors:  C S Cleeland; K M Ryan
Journal:  Ann Acad Med Singapore       Date:  1994-03       Impact factor: 2.473

8.  Prospective assessment of chemotherapy-induced peripheral neuropathy due to weekly paclitaxel in patients with advanced or metastatic breast cancer (CSP-HOR 02 study).

Authors:  Katsumasa Kuroi; Kojiro Shimozuma; Yasuo Ohashi; Kazufumi Hisamatsu; Norikazu Masuda; Ayano Takeuchi; Toshihiko Aranishi; Satoshi Morita; Shozo Ohsumi; Frederick H Hausheer
Journal:  Support Care Cancer       Date:  2008-12-17       Impact factor: 3.603

9.  The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology.

Authors:  N K Aaronson; S Ahmedzai; B Bergman; M Bullinger; A Cull; N J Duez; A Filiberti; H Flechtner; S B Fleishman; J C de Haes
Journal:  J Natl Cancer Inst       Date:  1993-03-03       Impact factor: 13.506

10.  Feasibility and validity of the Patient Neurotoxicity Questionnaire during taxane chemotherapy in a phase III randomized trial in patients with breast cancer: N-SAS BC 02.

Authors:  Kojiro Shimozuma; Yasuo Ohashi; Ayano Takeuchi; Toshihiko Aranishi; Satoshi Morita; Katsumasa Kuroi; Shozo Ohsumi; Haruhiko Makino; Hirohumi Mukai; Noriyuki Katsumata; Yoshihide Sunada; Toru Watanabe; Frederick H Hausheer
Journal:  Support Care Cancer       Date:  2009-03-28       Impact factor: 3.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.